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A B S T R A C T
The aim of our study was to assess cerebral vasoreactivity (CVR) in type 2 diabetes mellitus (DM2) and factors which
may influence on it. According to previous studies, evaluating CVR in DM2 on the similar way, the results were dubious.
For the evaluation CVR we used breath holding index (BHI) and transcranial Doppler ultrasound (TCD) in 50 patients
with DM2 and 50 sex- and age-matched healthy controls. We observed epidemiologic and clinic data, other vascular risk
factors and laboratory parameters. We found statistically significant difference in BHI between patients with DM2
(BHI=0.69±0.31) and age- and sex- matched healthy controls (BHI=1.33±0.28) (p<0.05). Because of a significant corre-
lation between BHI and age (p<0.001) in healthy controls we made an adjustment of BHI for age before further analyses
(BHIadj). In DM2 group we found a significant correlation between BHIadj and age (p=0.0004), fasting glycemia (p=
0.04), and albuminuria (p=0.04) (creatinine clearance in multivariate analysis (p=0.007)). Our study has shown that
CVR is impaired in DM2 patients and that it’s severity was associated with age, fasting glycemia and renal function.
Functional TCD is a very good screening method for detection and monitoring of cerebral microangiopathic changes in
DM2 patients.
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Introduction
Cerebrovascular diseases are the second cause of
death and the leading cause of disability1. We are still dis-
satisfied with the therapy of stroke. Therefore, an early
identification of cerebrovascular risk factors is needed.
We are particularly interested in the diabetic patients,
where relatively good treatment possibilities exist. As we
know from previous studies, the risk of stroke is in-
creased 2-to-3 fold in patients with the type 2 diabetes
mellitus (DM2)2 and if it is repeated, their stroke out-
comes and prognosis are poor3. Scientific interest is more
focused on changes in the big blood vessels in diabetic pa-
tients, but there are also changes in small ones. Cerebral
autoregulation is the ability to maintain a constant cere-
bral blood flow (CBF) despite changes in the cerebral
perfusion pressure and could be evaluated by the cere-
bral vasoreactivity (CVR), a hemodynamic parameter
representing the increase in the CBF velocity in response
to a vasodilatory stimulus, like hypercapnia4,5. Impaired
cerebrovascular reactivity is an indicator of the increased
risk of stroke6–8. Transcranial Doppler ultrasound (TCD)
is good, noninvasive and accurate method for the evalua-
tion of increase in mean flow velocity (MFV) in the cere-
bral arteries as a response to hypercapnia, induced by
the breath-holding test (BHT)9–16. It is well known that
patients with type 2 diabetes mellitus have impaired abil-
ity of the endothelium to properly maintain vascular
homeostasis17. Furthermore, diabetic patients have in-
creased risk of stroke as one of macrovascular complica-
tions of diabetes2,3. In previous studies, evaluation of the
CVR in the DM2 in a similar way, has given controversial
results. Some of them have shown no differences in the
CVR between DM2 patients and healthy controls18,19,
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and some of them have shown impaired the CVR but only
in a group with the microangiopathic complications20,21
and in a group of patients who had DM2 longer than 10
years22. The aim of this study was to assess cerebral
autoregulation in type 2 diabetes mellitus (DM2) and the
factors which may influence on it.
Materials and Methods
The study included 50 DM2 patients from outpatient
clinic of Department of Endocrinology, Diabetes and Me-
tabolic Disorders of Dubrava University Hospital and 50
sex- and age-matched healthy controls. Inclusion criteria
were type 2 diabetes mellitus, age of 18 to 70, ability to
participate in study and written Informed consent. The
exclusion criteria were poor insonation of the temporal
bone window, moderate or significant stenosis of the
main neck blood vessels, excluded with extracranial Dop-
pler ultrasound (Aloka 5500 Prosound), and non-cooper-
ative, unconscious or demented patient.
The TCD examination was performed through trans-
temporal window at a depth of 50 mm, on a TCD DWL
Multidop X4 (DWL Elektronische Systeme GmbH, Sip-
plingen, Germany) instrument with 2 MHz hand-held
pulsed wave probe, in supine position after 5-minute bed
rest. Each middle cerebral artery (MCA) was insonated
separately by standard protocol4,9–12 and mean flow ve-
locity (MFV) values were recorded in the rest and during
holding a breath for 30 seconds at the end of a normal in-
spiration. If they were not able to hold their breath for 30
seconds, they held it as long as they could and that time
was taken in a subsequent calculation. Vascular reactiv-
ity to hypercapnia was studied by calculating the breath-
-holding index (BHI). The index is obtained by dividing
the percent increase in the mean flow velocity (MFV) oc-
curred during the breath-holding by the length of time
(seconds) that subjects hold their breath after a normal
inspiration ((MFV at the end of BHT – rest MFV/rest
MFV)X100/second of breath-holding). Heart rate, arte-
rial pressure in arm, SaO2 were measured as in previous
studies are described12,13. Concerning the factors that
may influence on the CVR, we observed: age, sex, other
major vascular risk factors (hypertension, hyperlipemia,
atrial fibrillation, mild stenosis (<50%) of the main neck
blood vessels, obesity, smoking, consuming alcohol), pre-
vious neurological disturbances, diabetic complications
(retinopathy, nephropathy and polyneuropathy), dura-
tion of diabetes, waist circumference and laboratory pa-
rameters (fasting glycemia and two hours after meal
glycemia, glycated hemoglobin (HbA1c) total, high-den-
sity lipoprotein (HDL) and low-density lipoprotein (LDL)
cholesterol, triglycerides, C-reactive protein, hematocrit,
hepatic enzymes (AST – aspartate aminotransferase; ALT
– alanine transaminase; GGT – gamma-glutamyl trans-
peptidase), creatinine clearance and albuminuria in 24
hours urine). Statistical analyses were performed using
STATISTICA ver. 6.0 (StatSoft, Inc. Tulsa, OK)23 and
MedCalc (MedCalc Software, Mariakerke, Belgium). Da-
ta were expressed as means and SD if normally distrib-
uted and as median and range if not. Normality of distri-
bution was tested using Kolmogorov-Smirnov test. Prior
to further analysis variables that didn’t have normal dis-
tribution were normalized using logarithmic transforma-
tion. Between groups comparisons were made using Stu-
dent’s t-test. The linear regression analysis was perfor-
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TABLE 1
THE CLINICAL AND LABORATORY CHARACTERISTICS OF DM2 PATIENTS
Variable Mean (95% CI) SD Median Minimum Maximum
Age (years) 58.3 (54.9–61.9) 12.0 58.0 20.0 78.0
Duration (years) 9.6 (7.5–11.7) 7.4 9.5 1.0 33.0
Total cholesterol (mmol/L) 4.9 (4.6–5.3) 1.2 4.9 2.2 8.8
Triglycerides (mmol/L) 1.8 (1.5–2.1) 0.9 1.6 0.5 6.1
HDL cholesterol (mmol/L) 1.2 (1.1–1.3) 0.3 1.2 0.6 2.1
LDL cholesterol (mmol/L) 2.8 (2.6–3.1) 1.0 2.8 0.7 5.8
HbA1c (%) 9.0 (8.3–9.6) 2.1 8.5 5.5 13.7
Albuminuria (mg/day)* 191.1 (20.5–361.7) 600.1 10.9 0.1 3070.0
rsid7351224 Fasting glycemia (mmol/L) 7.6 (7.0–8.3) 2.2 7.2 4.1 14.2
2 hours after meal glycemia (mmol/L) 10.5 (9.6–11.4) 3.1 10.2 5.5 17.4
C-reactive protein (mg/L)* 5.3 (3.4–7.1) 6.5 2.2 0.2 25.6
Creatinine clearance (mL/s) 1.7 (1.6–1.9) 0.6 1.8 0.5 3.2
AST (U/L) 22.0 (19.5–24.5) 8.7 19.5 10.0 47.0
ALT (U/L) 28.5 (24.9–33.0) 15.8 24.5 6.0 87.0
Waist circumference (cm) 101.5 (97.3–105.7) 14.8 99.5 80.0 152.0
GGT (U/L) 46.3 (33.9–58.7) 43.5 31.5 10.0 173.0
Hematocrit L/L 0.406 (0.398–0.415) 0.03 0.408 0.324 0.460
All data are presented as mean (SD) or * median (range)
med to examine the relationship between BHI and age in
healthy controls. Results of the linear regression analysis
were used to adjust the BHI (BHIadj) values in the DM2
group according to age before further analyses. Analysis
of variance was used to assess the effects of other major
vascular risk factors, previous neurological disturbances,
and diabetic complications on the BHIadj in the DM2 pa-
tients. Associated risk for the BHI changes was calcu-
lated using univariate and multivariate linear regression
analysis. Multivariate linear regression analysis was done
using forward stepwise approach to minimize the num-
ber of variables in the model because of a small sample
size. Statistical significance was considered at p<0.05.
The study was approved by the local ethic committee and
each subject gave Informed consent.
Results
We studied 50 DM2 patients (33 men and 17 women)
and 50 sex- and age-matched healthy controls (26 men
and 24 women). The clinical and laboratory characteris-
tics of the DM2 patients are presented in Table 1. Car-
diorespiratory and MFV values with CO2 change are
shown in Table 2. The two groups had comparable car-
diorespiratory values under resting and hypercapnia.
Among the DM2 patients, 27/50 had hyperlipoprotei-
naemia, 11/50 atrial fibrillation, 40/50 hypertension, 7/50
mild stenosis of the main neck blood vessels, 12/50 were
obese, 10/50 smoked and 7/50 consumed alcohol. Con-
cerning the diabetic complications, 10/50 had retino-
pathy, 6/50 nephropathy, 8/50 polyneuropathy and 8/50
previous neurological disturbances. We found statisti-
cally significant difference for the BHI between patients
with the DM2 (BHI=0.69±0.31) and healthy controls
(BHI=1.33±0.28, p<0.001). As we found a significant
correlation between the BHI and age (r=0.62, p<0.001)
within the healthy controls group, we made an adjust-
ment for the BHI for age (BHIadj) prior to the further
analyses. In the DM2 group the BHIadj was, in the univa-
riate analysis, significantly associated with age (p<0.001),
fasting glycemia (p=0.04) and albuminuria (p=0.04). We
found no significant effects of other major vascular risk
factors, previous neurological disturbances and diabetic
complications in the DM2 patients on the BHIadj (p>0.05
for all). Using a multivariate analysis, the BHIadj was sig-
nificantly associated with age, creatinine clearance and
fasting glycemia (r for the model=0.64, p<0.0001) in the
DM2 group (Table 3).
Discussion and Conclusion
Acute stroke is still the leading cause of death and dis-
ability in modern society. In order to reduce incidence of
acute stroke the aim of our study was to define some
other risk factors for its development. Scientific atten-
tion is still more focused on the extracranial macro-
vascular complications of the diabetes mellitus than func-
tional changes in cerebral small vessels. We try to iden-
tify early enough moderate or significant stenosis of the
main neck blood vessels and then treat or observe them
as stroke prevention. Moreover, focus of our interest was
structural and functional changes in the cerebral small
vessels, signs of silent cerebral microangiopathy. From
all known methods which can assess the CVR, functional
TCD with the BHT was the most pleasant, easiest, no-
ninvasive, reproducible, real-time and bedside method.
As it was mentioned before, the fall in the cerebral perfu-
sion pressure have no influence on regional cerebral
blood flow in the healthy individuals because of the cere-
bral auto-regulation. These compensatory mechanisms
can be exhausted in some pathological conditions6,7. Re-
sults of our study showed that CVR was impaired and ce-
rebral autoregulation was exhausted in the DM2 pa-
tients. CVR was in relation with age, albuminuria, crea-
tinine clearance and fasting glycemia. In a group of
healthy controls we found significant correlation be-
tween CVR and age, like it was found in some previous
studie24,25 and we made correction of value in the DM2
group, prior to the further analyses. As we know, age is
an independent risk factor for stroke due to remodeling
of the cerebral small vessels26. After correction, we still
found correlation between age and CVR in the DM2 pa-
tients. A large epidemiological study showed that age and
previous stroke are the main predictors of a stroke in the
DM227. Among patients without a history of stroke, HbA1c
and smoking were predictors of the stroke and micro-
vascular complications. In the group of patient with his-
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TABLE 2
CARDIORESPIRATORY AND MFV VALUES WITH CO2 CHANGE
At rest Breath-hoding test
MFV dm (cm/s) 49±13.7 60±18
MFV control (cm/s) 65.3±7.4 90.8±11.8
SBP dm (mmHg) 130.1±6.1 133±7
SBP control (mmHg) 120±10 122±8
DBP dm (mmHg) 75±3 76±4
DBP control (mmHg) 70±4 72±4
Heart rate dm (beats/min) 66±4 67±2
Heart rate control (beats/min) 66±4 67±2
SaO2 dm (%) 97.8±0.3 98.2±0.4
SO2 control (%) 98.2±0.4 99.1±0.3
Definition of abbreviations: MFV – mean flow velocity, SBP –
systolic blood pressure, DBP – diastolic blood pressure, SaO2 –
oxigen saturation
TABLE 3
MULTIVARIATE REGRESSION ANALYSIS OF LABORATORY
PARAMETERS AND BHIadj
Laboratory parameters b p-level
Age 0.52 <0.001
Creatinine clearance 0.32 0.007
Fasting glycemia –0.25 0.030
tory of the stroke, predictors of the stroke were increased
total cholesterol and low HDL cholesterol concentra-
tion27. We found no correlation between CVR and men-
tioned risk factors. A decreased CVR indicates the pres-
ence of the preexisting vasodilatation, which reflects a
reduced reserve capacity of the cerebral autoregulation16
and an increased risk for stroke6–8,28. Intracerebral arte-
rioles could be already maximally dilated and unable to
react to stimuli16. Although vasodilatatory ability of brain
arterioles decreased with increasing disease duration19–22,
we did not find any correlation between them. Decreased
CVR may be responsible for a worse outcome of strokes
in the diabetic patients19. As we know from previous
studies, hyperglycemia leads to impaired vascular func-
tion through endothelial cell dysfunction and the HbA1c
is an indicator of the severity of diabetic cerebral micro-
angiopathy20,21, but we did not find any correlation be-
tween the HbA1c and CVR in our patients. Poor gly-
caemic control in the DM2 increases cardiovascular risk29.
In a large cohort study, fasting plasma glucose was found
to be a predictor for stroke in patients with the DM229.
Furthermore, fasting plasma glucose (FPG) was associa-
ted with incident ischemic cerebrovascular in increase
DM2 patients with FPG concentration above 5,6 mmol/L30.
We found correlation between the CVR and fasting gly-
caemia, which was in accordance with results of men-
tioned studies. Other published studies did not find cor-
relation between fasting glucose and CVR in DM2 pa-
tients19–22.
In our study, a significant correlation between BHIadj
and both creatinine clearance and albuminuria was found
in DM2 patients. However, some studies19,22 failed to find
correlation between CVR and albuminuria, like we did.
Although, albuminuria is consider as an independent
predictor of increasing levels of vascular risk factors and
macroangiopathic carotid alteration and microvascular
brain as it was confirmed by several studies31,32. Correla-
tion between albuminuria, creatinine clearance and BHI,
confirmed by our study, is in accordance with earlier ob-
servations that presence of renal microangiopathic chan-
ges can indicate existing cerebral microangiopathic chan-
ges and reverse too21. Our observation showed that CVR
was not associated, like in other cases19–22, with presence
of the additional risk factors, existing any diabetic com-
plication, inflammation factors, hepatic enzymes, waist
measurement. The limitation of our study is that there
were a small number of patients and controls. We present
now our preliminary results and continue with study. In
conclusion, the CVR is impaired and cerebral autoregu-
lation is exhausted in patients with the DM2. Results of
our study showed that age, fasting glycemia and albu-
minuria were in correlation with BHI in DM2 patients.
These results may carry important implications for the
prevention strategies in treatment of DM2 patients. Cer-
tainly, the CVR has to be regularly evaluated and fol-
lowed up for early therapeutical reaction and prevention
decompensation of the intracranial circulation and stro-
ke. The TCD is the most accurate method in the evalua-
tion and monitoring of the cerebral haemodynamic chan-
ges in the diabetic microangiopathy, especially silent
ones, and has to be performed periodically on a routine
basis in the diabetic patients. In order to carefully evalu-
ate CVR and cerebral autoregulation in DM2 patients
and to reduce the risk of stroke, further studies in a
greater number of patients are needed.
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OSLABLJENA MO@DANA VAZOREAKTIVNOST KOD BOLESNIKA SA [E]ERNOM BOLESTI TIP 2
S A @ E T A K
Cilj ovog istra`ivanja bio je procijeniti mo`danu vazoreaktivnost kod bolesnika sa {e}ernom bolesti tip 2 (DM2), te
faktore koji na nju utje~u. Prema dosada{njim studijama koje su sli~no procjenjivale mo`danu vazoreaktivnost kod
DM2, rezultati su dvojbeni. Procjenu stanja mo`dane vazoreaktivnosti smo radili mjerenjem indeksa zadr`avanja daha
(BHI) koriste}i Transkranijalni dopler (TCD) krvnih `ila na 50 bolesnika sa DM2 i 50 zdravih, po dobi i spolu odgo-
varaju}ih kontrola. Promatrani su uz epidemiolo{ke i klini~ke podatke i ostali vaskularni rizi~ni faktori te laborato-
rijski parametri. Na|ena je statisti~ki zna~ajna razlika u indeksu zadr`avanja daha izme|u bolesnika sa DM2 (BHI=
0,69±0,31) i zdravih ispitanika (BHI=1,33±0,28, p<0,05). Zbog na|ene zna~ajne korelacije BHI s dobi (p<0,001) kod
zdravih, ra|ena je korekcija vrijednosti u dijabeti~ara za dob prije daljnje analize (BHIadj). U skupini DM2 na|ena je
korelacija BHI osim sa dobi (p<0,001) i sa GUK-om nata{te (p=0,04) i albuminurijom (p=0,04), te u multivarijantnoj
analizi s kreatinin klirensom. Na{e istra`ivanje je pokazalo da je kod bolesnika sa DM2 oslabljena cerebrovaskularna
reaktivnost, a stupanj o{te}enje je povezan sa dobi, GUK-om nata{te i renalnom funkcijom. Funkcionalni TCD je kod
njih dobra skrining metoda za otkrivanje i pra}enje cerebralnih mikroangiopatskih promjena.
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